gatekeeper mutation ͉ imatinib resistance ͉ kinase inhibitor
Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-Abl T315I , however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-Abl T315I , with minimal toxicity against Bcr-Ablnegative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl T315I . These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.
gatekeeper mutation ͉ imatinib resistance ͉ kinase inhibitor I matinib (Gleevec) inhibits Bcr-Abl, the deregulated tyrosine kinase that causes chronic myeloid leukemia (CML) (1) and is the first-line therapy for the disease. Responses in CML patients who begin imatinib treatment in chronic phase are durable (2) , but relapse is common in accelerated and blastic phase (3) (4) (5) . Even in patients reaching a complete cytogenetic response, residual disease remains detectable by sensitive PCR techniques, suggesting a continued threat of relapse (6, 7) . Relapses can often be traced to emergence of CML subclones expressing Bcr-Abl with mutations in the kinase domain that confer varying degrees of resistance to imatinib (8, 9) .
The imatinib family member nilotinib (AMN107; Tasigna) and the Src/Abl inhibitor dasatinib (BMS-354825; Sprycel) are Abl kinase inhibitors with enhanced potency against native Bcr-Abl compared with imatinib (Ϸ30-fold and Ϸ325-fold, respectively), and these inhibitors are also effective against most imatinib-resistant Bcr-Abl mutants except Bcr-Abl T315I (10) (11) (12) . We recovered only the Bcr-Abl T315I mutant in vitro in the simultaneous presence of nilotinib and dasatinib (13) . Emerging clinical data confirms that patients harboring Bcr-Abl T315I are resistant to nilotinib (14) and dasatinib (15) , and Bcr-Abl T315I is frequently detected in patients with resistance to these inhibitors (14) (15) (16) . Thus, an inhibitor of Bcr-Abl T315I will be essential to circumvent resistance to Abl kinase inhibitor therapy for CML. Here, we report that the Bcr-Abl T315I inhibitor SGX393 suppresses outgrowth of all Bcr-Abl escape mutants when combined with nilotinib or dasatinib.
Results
Catalytic Activity of Abl T315I Is Inhibited by SGX393. Application of x-ray crystallographic lead discovery and structure-guided optimization identified 1 [supporting information (SI) Fig. 6 A] as an inhibitor of Abl and Abl T315I , binding an active conformation of the Abl kinase domain (SI Fig. 6 ). Further development yielded SGX393, an inhibitor of native Bcr-Abl and most imatinib-resistant mutants, including Bcr-Abl T315I , whose structure will be reported elsewhere. Recently, the crystal structure of Abl T315I in complex with a pyrrolopyridine inhibitor related to 1 was reported (17) .
To establish that SGX393 directly targets Abl and Abl T315I , we compared SGX393 to imatinib, nilotinib, and dasatinib in biochemical assays (10, 18, 19) . SGX393 was comparable in potency to dasatinib in assays of Abl autophosphorylation and Ablcatalyzed peptide substrate phosphorylation (SI Fig. 7 ). In the case of Abl T315I , only SGX393 was effective (Fig. 1 ).
Among Ͻ 25 nM (M244V, T315A, T315I, M351T, F359V, V379I,  L387M, H396P , and H396R), IC 50 Ͻ 300 nM (Q252H, Y253H, E255K, and F311L), and IC 50 Ͼ 500 nM (G250E, Y253F, E255V, and F317L). SGX393 also inhibited growth of K562 and BV173 CML cell lines but not Bcr-Abl-negative leukemia cell lines. Growth of parental Ba/F3 cells was not affected by SGX393 at Ͻ2 M (Table 1) .
SGX393 Inhibits Colony Formation by Murine Bone Marrow Cells
Expressing Bcr-Abl T315I . To test the efficacy of SGX393 in primary hematopoietic cells, murine bone marrow was infected with retrovirus expressing native or mutant Bcr-Abl. All of the drugs inhibited colony formation of cells infected with native Bcr-Abl retrovirus, but only SGX393 was effective on cells expressing Bcr-Abl T315I . Minimal toxicity of SGX393 was observed in cytokine-stimulated controls (SI Fig. 9 ).
Bcr-Abl T315I -Driven Tumor Growth Is Inhibited by SGX393 in a Xenograft Model. To evaluate SGX393 in vivo, nude mice were s.c. injected with Ba/F3 cells expressing Bcr-Abl T315I . On day 9 (average tumor volume, 100 mm 3 ), treatment was started with vehicle, imatinib, or SGX393 at 50 mg/kg, administered i.p. every 12 h for 12 days. SGX393 effectively inhibited tumor growth in mice compared with vehicle-or imatinib-treated mice ( Fig. 2A) . Phospho-CrkL-specific immunoblot analysis of tumor tissue collected 2 h after the final treatment confirmed inhibition of CrkL phosphorylation in mice receiving SGX393 but not imatinib or vehicle (Fig. 2B) . Additionally, SGX393 and imatinib inhibited tumor growth in xenograft experiments that used K562 or Ba/F3 cells expressing native Bcr-Abl (SI Fig. 10 ). The relatively short half-life (2.9 h in BALB/c mice) of SGX393 in mice may explain the incomplete retardation of tumor growth.
SGX393 Inhibits Bcr-Abl T315I Kinase Activity in Primary CML and B-ALL Cells. Peripheral blood mononuclear cells from a CML patient in lymphoid blast crisis harboring a T315I mutation were exposed to each of the inhibitors. Inhibition of Bcr-Abl T315I kinase activity was assessed by immunoblot analysis with a total CrkLspecific antibody (Fig. 3) . We observed a reduction in the level of phosphorylation of the Bcr-Abl substrate CrkL by SGX393, but not the other inhibitors. FACS analysis of intracellular phosphotyrosine levels yielded analogous results (SI Fig. 11A ). Similar findings were observed for Bcr-Abl T315I cells from a patient with Ph-positive B-ALL (SI Fig. 11B ).
To assess toxicity against normal hematopoietic progenitors, bone marrow mononuclear cells from three healthy individuals were cultured with SGX393 (SI Fig. 12 ). We observed minimal toxicity at concentrations of SGX393 up to 2 M. At 5 M SGX393, granulocyte/macrophage (CFU-GM) and erythroid (BFU-E) colony formation was reduced to 60-70% of controls.
The Resistance Profile of SGX393 Does Not Include Novel Sites. To establish a resistance profile for SGX393, we used our previously validated Ba/F3 cell line-based mutagenesis screen (13) . Of note, not every possible mutation is necessarily represented in each experiment (13) . We observed a concentration-dependent reduction of surviving subclones, ranging from 100% (120 nM SGX393) to 9% (1,920 nM SGX393) of wells exhibiting outgrowth (SI Table 2 ). Subclones expressing native Bcr-Abl were recovered rarely at SGX393 concentrations Ͼ240 nM (SI Table  2 ). Sequencing was confined to the kinase domain of Bcr-Abl.
At 240 nM SGX393, exchanges at 10 residues known to confer resistance to imatinib accounted for 98.5% of recovered mutated subclones ( Fig. 4 and SI Table 2 ). At 480 nM SGX393, mutations were limited to seven positions, with exchanges at G250 and F317 accounting for 64.1% of recovered mutated subclones. Mutations recovered at 1,920 nM SGX393 were confined to L248R, G250E, Y253F, E255V, and F317V, with G250E and F317V accounting for 69.2% of the total.
Because the L248R mutation persisted throughout the SGX393 screen but was not represented in the Ba/F3 cell panel, we tested GST-Abl L248R in a peptide substrate-based tyrosine phosphorylation assay (11) . The IC 50 values were: Ͼ5,000 nM (imatinib), 2,328 nM (SGX393), 239 nM (nilotinib), and 0.8 nM (dasatinib) (data not shown).
No mutations involving residue T315 or unique exchanges that confer high level resistance to SGX393 were observed among the nearly 1,000 resistant subclones analyzed in this study. Rather, most of the recovered mutations had been documented in connection with imatinib resistance (7, 20-24). GST-Abl Because T315I inhibitors, such as SGX393, may be used as second-line therapy for CML patients with the T315I mutation, we established the resistance profile when starting from Ba/F3 cells expressing Bcr-Abl T315I . The distribution of mutations was similar to the native Bcr-Abl experiment, except for a striking decline in mutations at residue F317 (SI Table 3 ). This may indicate that two closely spaced mutations within the ATP binding site adversely affect kinase activity to an extent incompatible with survival of these subclones (25) . Further studies will be necessary to explain this difference.
Exposure of Ba/F3 cells expressing native Bcr-Abl to a range of combinations of SGX393 and imatinib, dasatinib, or nilotinib revealed additive to synergistic cytotoxicity (SI Fig. 13 ) consistent with findings for imatinib combined with dasatinib (26) or nilotinib (10, 27) . Table 4 ). However, outgrowth was not completely suppressed even at the highest tested combination (4,000 nM imatinib and 1,920 nM SGX393) with L248R, Y253H, and E255V persisting (Fig. 5) .
Consistent with the activity of nilotinib against most imatinibresistant Bcr-Abl mutants and the potency of SGX393 against the T315I mutant, outgrowth at intermediate concentrations of these inhibitors was confined to three mutations: L248R, Y253H, and E255V. In the presence of 1,000 nM nilotinib and 240 nM SGX393, outgrowth of resistant subclones was completely suppressed. In total, 10 of 16 tested SGX393-nilotinib combinations abrogated outgrowth of resistant subclones (Fig. 5 and SI Table 5 ).
The combination of SGX393 with dasatinib was also tested for 
Native L248 G249 G250 Q252 Y253 E255 F311 F317 Native L248 G249 G250 Q252 Y253 E255 F311 F317 Native L248 G249 G250 Q252 Y253 E255 F311 F317 Table 2 Table 6 ). However, no outgrowth was observed in the presence of 25 nM dasatinib and 960 nM SGX393. In total, 11/16 tested SGX393-dasatinib combinations were sufficient to completely suppress outgrowth of resistant subclones.
Discussion
Imatinib has changed the landscape of CML therapy, inducing complete cytogenetic responses in 87% of patients diagnosed with chronic phase disease (2) . Resistance in early chronic phase is uncommon, although relapses do occur, particularly in patients with high-risk Sokal scores (2) . In contrast, acquired resistance is frequent in patients who start imatinib in accelerated or blastic phase (3) (4) (5) 28) . Relapse is frequently due to Bcr-Abl kinase domain mutations that impair imatinib binding (21, 22, 29) . Nilotinib and dasatinib have largely addressed this issue, maintaining activity against most imatinib-resistant mutants except Bcr-Abl T315I (14, 15, 30) . The frequency of T315I in patients with resistance to nilotinib or dasatinib suggests that this mutant may emerge as a common mechanism of failure to second-line Abl kinase inhibitor therapy (14-16, 31, 32) , consistent with predictions based on in vitro profiling and mutagenesis screens (11-13, 31, 33-36) . Thus, the full potential of Abl kinase inhibitor therapy in patients with CML, particularly those with advanced disease, will depend on effectively targeting the Bcr-Abl T315I mutant. SGX393 activity in cell proliferation assays extended to a wide range of mutations, including T315A, which has been recovered from several patients resistant to dasatinib (16, 31) . The key exceptions involve F311, F317, and certain P-loop mutations, especially E255V (IC 50 , 2,210 nM). However, E255V is inhibited to some extent by nilotinib (IC 50 , 430 nM) and dasatinib (IC 50 , 11 nM), providing a rationale for combined Abl inhibitor therapy (SI Fig. 3B) (26, 37, 38) . Steady-state trough plasma levels in patients are 3,700 nM for nilotinib and 150 nM for dasatinib (14, 15) .
In mutagenesis assays, SGX393 controlled the outgrowth of native Bcr-Abl, Bcr-Abl T315I , and most mutants associated with imatinib resistance (Fig. 4 and SI Table 2 ). However, similar to results obtained in cell proliferation assays, mutations in and around the P-loop and at positions F311 and F317 remain vulnerabilities. Because dual combinations of currently available Abl inhibitors selected for T315I in vitro (13), we reasoned that combinations that include SGX393 might eliminate the outgrowth of resistant subclones. Indeed, when SGX393 was included with nilotinib or dasatinib, outgrowth of resistant subclones was reduced to zero (Fig. 5) . Although further pharmacokinetic analysis of SGX393 and related compounds will be necessary, it is remarkable that even the lowest dose of SGX393 tested in combination with clinically relevant concentrations of nilotinib or dasatinib completely suppressed the emergence of resistant clones.
The T315I mutation is emerging as a common mechanism of failure to second-line Abl kinase inhibitors (16, 30, 31, 39, 40) . Thus, even in these advanced cases, Bcr-Abl remains the critical therapeutic target. At this point, reports of successful salvage therapy for CML patients who acquire the T315I mutation are limited to small clinical trials and case reports (41, 42) . Because SGX393 is active against native Bcr-Abl and the Bcr-Abl T315I mutant, monotherapy with an inhibitor of this type might be sufficient to induce responses in patients harboring only BcrAbl T3151 . However, multiple mutation types are often detectable in patients with imatinib failure (22, 31) and patients subsequently failing dasatinib or nilotinib may harbor mutant clones other than T315I (30, 40, 41) . Compound mutations, defined as more than one codon change in the same BCR-ABL mRNA, have also been detected in so far rare cases (31) . Thus, the full clinical potential of T315I inhibitors may be realized in combi- nations with nilotinib or dasatinib. Of note, combination treatment is not expected to inhibit Bcr-Abl-independent resistance or to target CML stem cells. In light of evidence that nilotinib and dasatinib impinge on several nonkinase targets (43) , there is also potential for side effects in patients because of off-target effects. The combination treatment suggested here may be useful to reduce the incidence of Bcr-Abl mutants in patients with Ph-positive leukemia and possibly eliminate Bcr-Abl-dependent resistance.
Materials and Methods
Inhibitors. Inhibitor stock solutions (10.0 mM) were stored at Ϫ20°C, and diluted just before use. SGX393 may be requested from SGX Pharmaceuticals.
Kinase Autophosphorylation Assays with GST-Abl Kinase Domains. Kinase assays, using tyrosine-dephosphorylated GST-Abl and mutant GST-Abl fusion proteins (c-Abl amino acids 220 -498), were performed as described in ref. 44 .
In Vitro Peptide Substrate Phosphorylation Assays with GST-Abl Kinase Domains. The effects of SGX393 on the catalytic activity of tyrosine dephosphorylated GST-Abl kinase were assessed by using a synthetic peptide substrate as described in refs. 44 and 45. We also profiled the inhibitors imatinib, nilotinib, and dasatinib in all experiments for comparison.
Kinase Selectivity Profile of SGX393. SGX393 (1,000 nM) was profiled against the T315I mutant of Abl and 177 off-target kinases, using the fluorescence resonance energy transfer-based SelectScreen assay (Invitrogen).
Cell Lines. Ba/F3 transfectants expressing native or mutant Bcr-Abl were maintained in RPMI medium 1640 supplemented with 10% FCS, 1 unit/ml penicillin G, and 1 mg/ml streptomycin (complete media) at 37°C and 5% CO Colony-Forming Assays with Murine Bone Marrow Cells. Murine bone marrow cells were prestimulated with IL-3 (3 ng/ml), IL-6 (5 ng/ml), and SCF (50 ng/ml) for 16 h. Cells were transduced twice with 1 ϫ 10 6 plaque-forming units of murine stem cell retrovirus expressing native Bcr-Abl or mutant Bcr-Abl (Y253H, E255K, T315I, M351T, or H396P) and plated in Methocult without cytokines in the absence or presence of imatinib (500 or 5,000 nM), SGX393 (1-1,000 nM), nilotinib (1-1,000 nM), or dasatinib (0.1-100 nM). Colonies were quantified 7 days after plating. Control experiments were done in the presence of IL-3 (3 ng/ml), IL-6 (5 ng/ml), and SCF (50 ng/ml).
Bcr-Abl T315I Murine Xenograft Model. Nude mice (12 per condition) were s.c. implanted with K562 or Ba/F3 cells expressing native Bcr-Abl or Bcr-Abl T315I (2 ϫ 10 6 cells per mouse). At a tumor volume of 100 mm 3 , treatment by i.p. injection was initiated with vehicle (50% PEG400, 50% saline), imatinib, or SGX393 at 50 mg/kg every 2 days for 12-13 days. At study end, plasma levels of SGX393 were measured, and CrkL phosphorylation in tumor tissue was determined by immunoblot analysis with a phospho-CrkL-specific antibody. Inhibitor concentrations in plasma from three mice per group were determined by an internal standard LC/MS/MS method. Tissues for immunoblot analysis were harvested 2 h after the final dosing.
Hematopoietic Colony Forming Assays of Normal Bone Marrow. Bone marrow mononuclear cells (AllCells) from three normal individuals were cultured with SGX393. Cells (5 ϫ 10 4 ) were plated in methylcellulose containing 50 ng/ml SCF, 10 ng/ml GM-CSF, and 10 ng/ml IL-3 (Methocult GF H4534; Stem Cell Technologies) to assess CFU-GM colony formation or media also containing 3 units/ml erythropoietin (Methocult GF H4434; Stem Cell Technologies) to assess BFU-E colony formation. Colonies were scored at 14 days.
Ex Vivo Exposure of Bcr-Abl T315I Patient Samples to SGX393. After obtaining informed consent, peripheral blood mononuclear cells from a patient with CML L-BC and a patient with B-ALL, each with a Bcr-Abl T315I mutation, were isolated by Ficoll centrifugation. RT-PCR and sequence analysis confirmed that each sample predominantly contained the Bcr-Abl T315I mutant. Mononuclear cells (5 ϫ 10 6 per well) were cultured overnight alone or with imatinib (1 M), dasatinib (50 nM), nilotinib (200 nM), or SGX393 (50 nM, 500 nM). Cells lysates were subjected to immunoblot analysis with total CrkL-specific antibody C-20 (Santa Cruz Biotechnology). Phosphorylated and nonphosphorylated CrkL, distinguished based on band migration, were quantified by densitometry on a Lumi-Imager (Roche). In parallel experiments, mononuclear cells (2 ϫ 10 5 ) were cultured overnight alone or with imatinib (1,000 nM), dasatinib (50 nM), nilotinib (200 nM), or SGX393 (10, 20, 50, 100, and 500 nM). Cells were fixed and permeabilized as per manufacturer's instructions (Caltag), incubated with 4G10-FITC phosphotyrosine antibody (2 g; BD Biosciences) for 1 h, washed twice with PBS supplemented with 1% BSA and 0.1% NaN3, and fixed in 1% formaldehyde. FITC signal intensity was analyzed on a FACSAria instrument (BD Biosciences), and results are reported as fold increase in mean fluorescence intensity relative to unstained controls.
Accelerated Mutagenesis Screen. Ba/F3 cells expressing native Bcr-Abl were treated overnight with N-ethyl-N-nitrosourea (ENU; 50 g/ml), pelleted, resuspended, and distributed into 96-well plates (1 ϫ 10 5 cells per well) in complete media supplemented with SGX393. Wells were visually inspected for media color change and for cell growth every 2 days throughout the 28-day experiment. The contents of wells exhibiting outgrowth were transferred to wells containing 2-ml of complete media supplemented with SGX393 at the same concentration as in the initial well. If growth was observed in all wells of a given condition, 24 representative wells were expanded. At confluency, cells were collected by centrifugation, DNA was extracted by using a DNEasy Tissue kit (Qiagen), the Bcr-Abl kinase domain was amplified by using primers B2A (5Ј-TTCAGAAGCTTCTCCCTGACAT-3Ј) and ABL4065 (5Ј-TGAGTTCATAGACCT-TCTCTGG-3Ј), PCR products were bidirectionally sequenced (Agencourt), and chromatograms were analyzed by using Mutation Surveyor software (SoftGenetics). The accelerated mutagenesis screen for SGX393 in combination with imatinib, nilotinib, or dasatinib was conducted in the same manner except that a second inhibitor was included.
